Search clinical trials for: Linagliptin metformin

Total 2675 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Healthy

United States
Evidem Consultores SL
Boehringer Ingelheim; Merck Serono International SA; European Commission

Unknown

Prevention of Microvascular Complications in Prediabetes e-PREDICE Study (ePREDICE)

PreDiabetes

Spain
Boehringer Ingelheim

Completed

Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Diabetes Mellitus, Type 2

Bangladesh, Belgium, Canada, China, Germany, Guatemala, Hong Kong, India, Lebanon, Mexico, Peru, Philippines, Spain, Taiwan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Unknown

Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes

Insulin Resistance | Prediabetic State

Mexico
Boehringer Ingelheim

Completed

Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin

Healthy

China
Boehringer Ingelheim

Completed

Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet

Diabetes Mellitus, Type 2

Canada
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Merck Sharp & Dohme LLC

Completed

A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
Boehringer Ingelheim

Completed

Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers

Healthy

Germany
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Type 2 Diabetes
GC Biopharma Corp

Recruiting

A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions

Healthy Volunteers

Korea, Republic of
Baylor College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes

Type 1 Diabetes

United States
GC Biopharma Corp

Recruiting

A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions

Healthy Volunteers

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

Type 2 Diabetes
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, India, Israel, Malaysia, Mexico, Philippines, Puerto Rico, Russian Federation, Sri Lanka, Thailand, Ukraine
Boehringer Ingelheim

Completed

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Healthy

Germany
EMS

Not yet recruiting

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Type 2 Diabetes Mellitus
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine (RESCATHEME)

Insulin Resistance | Prediabetic State | Impaired Glucose Tolerance

Mexico
Boehringer Ingelheim
Eli Lilly and Company

Completed

Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

Diabetes Mellitus, Type 2

China, Malaysia, Philippines, Vietnam
Merck Sharp & Dohme LLC

Completed

Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)

Type 2 Diabetes Mellitus
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

Healthy

Germany
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

Healthy

Germany
Shahid Beheshti University of Medical Sciences

Recruiting

Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients

Polycystic Ovary Syndrome | Infertility | ART

Iran, Islamic Republic of
Merck Sharp & Dohme LLC

Completed

A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)

Type 2 Diabetes
Dong Wha Pharmaceutical Co. Ltd.

Completed

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers

Healthy Subjects

Korea, Republic of
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes (PRELLIM)

Insulin Resistance | Prediabetic State

Mexico
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator

Healthy Subjects
Merck Sharp & Dohme LLC

Completed

Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

Type 2 Diabetes Mellitus
Dong Wha Pharmaceutical Co. Ltd.

Completed

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition

Healthy Subjects

Korea, Republic of
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)

Healthy

Egypt
Shanghai 10th People's Hospital

Completed

Non-alcoholic Fatty Liver Disease and Its Treatment

NAFLD
Boehringer Ingelheim
Eli Lilly and Company

Completed

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Healthy

Germany
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Unknown

Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes (4T)

Insulin Resistance | Prediabetic State

Mexico
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects

Healthy Subjects

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

Healthy

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects

Healthy
Services Hospital, Lahore

Completed

Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes

Diabetes, Type 2

Pakistan
University of Pisa
Merck Sharp & Dohme LLC

Completed

Metformin and Sitagliptin in Women With Previous Gestational Diabetes

Pre-diabetes

Italy
LG Life Sciences

Completed

Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study) (STABLE)

Type 2 Diabetes Mellitus

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379

Type 2 Diabetes Mellitus

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)

3

Subscribe